Henry S Heine

Henry S Heine,

PRG DIR & RES ASO PROF

Department: MD-INST FOR THERAPEUTIC INNOV
Business Phone: (407) 313-7062

Teaching Profile

Courses Taught
2018-2021
GMS5905 Special Topics in Biomedical Sciences
2018
GMS7979 Advanced Research

Research Profile

Open Researcher and Contributor ID (ORCID)

0009-0002-4746-4892

Publications

2024
A Resistance-Evading Antibiotic for Treating Anthrax.
Research square. [DOI] 10.21203/rs.3.rs-3991430/v1. [PMID] 38585816.
2023
The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei.
Antibiotics (Basel, Switzerland). 12(3) [DOI] 10.3390/antibiotics12030506. [PMID] 36978372.
2023
Tolfenpyrad displays Francisella -targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity
Microbiology Spectrum. 11(6) [DOI] 10.1128/spectrum.02713-23. [PMID] 37800934.
2021
In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.
Antimicrobial agents and chemotherapy. 65(5) [DOI] 10.1128/AAC.02385-20. [PMID] 33593844.
2020
Validated Methods for Removing Select Agent Samples from Biosafety Level 3 Laboratories.
Emerging infectious diseases. 26(11):2586-2590 [DOI] 10.3201/eid2611.191630. [PMID] 33079040.
2019
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.
Antimicrobial agents and chemotherapy. 63(12) [DOI] 10.1128/AAC.00834-19. [PMID] 31548183.
2017
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
Antimicrobial agents and chemotherapy. 61(9) [DOI] 10.1128/AAC.00788-17. [PMID] 28696235.
2017
In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.
Antimicrobial agents and chemotherapy. 61(9) [DOI] 10.1128/AAC.00612-17. [PMID] 28674048.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Bacillus Anthracis Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial Agents and Chemotherapy. 61(10) [DOI] 10.1128/AAC.01103-17.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Francisella Tularensis Schu S4 Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial agents and chemotherapy. 61(8) [DOI] 10.1128/AAC.00448-17. [PMID] 28559261.
2016
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrobial agents and chemotherapy. 60(3):1834-40 [DOI] 10.1128/AAC.02887-15. [PMID] 26824958.
2015
In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.
Antimicrobial agents and chemotherapy. 59(4):1919-21 [DOI] 10.1128/AAC.04548-14. [PMID] 25583720.
2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Antimicrobial agents and chemotherapy. 58(6):3276-84 [DOI] 10.1128/AAC.02420-14. [PMID] 24687492.
2013
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
Antimicrobial agents and chemotherapy. 57(5):2010-5 [DOI] 10.1128/AAC.02504-12. [PMID] 23403418.
2012
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy. 56(1):513-7 [DOI] 10.1128/AAC.05724-11. [PMID] 22064542.
2012
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy. 56(3):1229-39 [DOI] 10.1128/AAC.01109-10. [PMID] 22155821.
2011
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy. 55(6):2623-8 [DOI] 10.1128/AAC.01374-10. [PMID] 21486959.
2011
Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.
Journal of clinical microbiology. 49(5):1956-60 [DOI] 10.1128/JCM.00142-11. [PMID] 21411569.
2011
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy. 55(2):822-30 [DOI] 10.1128/AAC.00818-10. [PMID] 21115791.
2010
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
Antimicrobial agents and chemotherapy. 54(3):991-6 [DOI] 10.1128/AAC.00820-09. [PMID] 20047912.
2010
Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Antimicrobial agents and chemotherapy. 54(10):4471-3 [DOI] 10.1128/AAC.00210-10. [PMID] 20643899.
2010
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Molecular and cellular probes. 24(3):154-60 [DOI] 10.1016/j.mcp.2010.01.003. [PMID] 20100564.
2010
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Antimicrobial agents and chemotherapy. 54(5):1678-83 [DOI] 10.1128/AAC.00737-08. [PMID] 20145081.
2009
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy. 53(11):4718-25 [DOI] 10.1128/AAC.00802-09. [PMID] 19687233.
2008
Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies.
Carbohydrate research. 343(16):2783-8 [DOI] 10.1016/j.carres.2008.05.021. [PMID] 18558401.
2008
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
Antimicrobial agents and chemotherapy. 52(9):3350-7 [DOI] 10.1128/AAC.00360-08. [PMID] 18606841.
2008
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy. 52(11):3973-9 [DOI] 10.1128/AAC.00453-08. [PMID] 18725437.
2008
Petrobactin is produced by both pathogenic and non-pathogenic isolates of the Bacillus cereus group of bacteria.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 21(5):581-9 [DOI] 10.1007/s10534-008-9144-9. [PMID] 18459058.
2008
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy. 52(7):2486-96 [DOI] 10.1128/AAC.01439-07. [PMID] 18458134.
2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases. 196(5):782-7 [PMID] 17674322.
2007
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Antimicrobial agents and chemotherapy. 51(4):1373-9 [PMID] 17296745.
2007
Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.
Journal of medicinal chemistry. 50(15):3681-5 [PMID] 17608397.
2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Antimicrobial agents and chemotherapy. 51(12):4351-5 [PMID] 17875992.
2006
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
Proceedings of the National Academy of Sciences of the United States of America. 103(20):7813-6 [PMID] 16672361.
2005
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy. 49(12):5099-106 [PMID] 16304178.

Grants

Nov 2023 – Mar 2024
In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels
Role: Co-Investigator
Funding: Melinta Therapeutics,Inc via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Apr 2023 ACTIVE
In vitro testing of 100 isolates of B. pseudomallei
Role: Principal Investigator
Funding: VENATORX PHARMACEUTICALS via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Sep 2022 ACTIVE
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST via DEFENSE THREAT REDUCTION AGENCY
Apr 2022 – Mar 2024
In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels
Role: Co-Investigator
Funding: CENTER FOR DISCOVERY AND INNOVATION via NATL INST OF HLTH NIAID
Feb 2022 – Jun 2022
Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Feb 2022 – Mar 2022
In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels
Role: Principal Investigator
Funding: PROKARYOTICS
Jan 2022 – Jul 2023
Merck Study Agreement
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Aug 2021 – Aug 2022
In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Mar 2021 ACTIVE
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Role: Principal Investigator
Funding: ADVANCED TECHNOLOGY INTERNATIONAL via DEFENSE THREAT REDUCTION AGENCY
Feb 2021 – Jun 2021
Evaluation of air purification methods for SARS-CoV-2
Role: Co-Investigator
Funding: HELEN OF TROY
Feb 2021 – May 2021
Teixobactin Development for Anthrax
Role: Principal Investigator
Funding: NOVOBIOTIC PHARMACEUTICALS via NATL INST OF HLTH NIAID
Nov 2020 – Dec 2021
Project Bioshield
Role: Co-Investigator
Funding: SPERO THERAPEUTICS
Oct 2020 – Nov 2020
MICs for Wockhardt WCK-5222
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
May 2020 – Jul 2020
KBP Biosciences Research Agreement – In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: *KBP BIOSCIENCES USA
Apr 2020 ACTIVE
Battelle Subcontract 778380 SAB Year 1
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST via DEFENSE THREAT REDUCTION AGENCY
Feb 2020 – Sep 2022
Evaluation of antimicrobial peptides for Biodefense
Role: Principal Investigator
Funding: UNIV OF TEXAS AUSTIN via DEFENSE THREAT REDUCTION AGENCY
Apr 2019 – Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Apr 2019 – Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 PK Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Jan 2019 – Oct 2020
In vitro testing of the 40 isolate panel of B. pseudomallei isolates
Role: Principal Investigator
Funding: VENATORX PHARMACEUTICALS via DEFENSE THREAT REDUCTION AGENCY
Nov 2018 – Apr 2019
In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens
Role: Principal Investigator
Funding: SPERO THERAPEUTICS via NATL INST OF HLTH NIAID
Jul 2018 – Mar 2019
Confirmatory Efficacy Study in Bp Infected Mice
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Feb 2018 – Oct 2018
Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Nov 2017 – Jun 2018
Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Nov 2017 – Jan 2018
Evaluation of EBX-205 against of B. Pseudomallei in virto
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Oct 2017 – Feb 2018
MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei.
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
Sep 2017 – Dec 2017
Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Sep 2017 – Sep 2018
Pharmacokinetic analysis of nonhuman primate data for US Army
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Aug 2017 – Jan 2018
ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Aug 2017 – Jan 2018
Exhibit N – MIC testing of BSC 3 extended MIC Panel in connection with Achaogens C-Scape project as outlined in University of Florida proposal ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Aug 2017 – Jan 2018
ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
May 2017 – Aug 2017
Salary for protocol development and ACURO review
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Mar 2017 – May 2017
WITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Oct 2014 – Dec 2017
HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents
Role: Project Manager
Funding: EMERGENT BIOSOLUTIONS via US DEPT OF DEFENSE
Sep 2014 – Dec 2016
Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS via DEFENSE THREAT REDUCTION AGENCY
Jul 2012 – Jul 2017
In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs.
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2012 – Apr 2016
EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1
Role: Principal Investigator
Funding: GLAXOSMITHKLINE via US DEPT OF DEFENSE

Contact Details

Phones:
Business:
(407) 313-7062
Emails:
Addresses:
Business Mailing:
RESEARCH ACADEMIC CENTER AT LAKE NONA
6550 SANGER RD
ITI
ORLANDO FL 328277445
Business Street:
U. FLORIDA RESEARCH ACADEMIC CENTER AT LAKE
ITI, DEPT MEDICINE
ORLANDO FL 32832